论文部分内容阅读
胰升血糖素样肽-1受体激动剂(GLP-1RA)作用机制独特,是近年备受瞩目的新型降糖药物,每日皮下注射GLP-1RA(艾塞那肽及利拉鲁肽等)的降糖疗效已获得广泛临床验证。GLP-1RA周制剂,如缓释艾塞那肽、阿必鲁肽和度拉糖肽已陆续在欧美上市,Semaglutide已进入Ⅲ期临床试验阶段。现有临床数据表明,GLP-1RA周制剂能安全有效地控制血糖,且低血糖风险低,体重降低,注射次数减少,患者用药依从性提高。本文将对几种GLP-1RA周制剂的疗效及重要安全性问题进行回顾总结。
Glucagon-like peptide-1 receptor agonist (GLP-1RA) has a unique mechanism of action and is a new type of hypoglycemic drug that has drawn much attention in recent years. GLP-1RA (exenatide and liraglutide, etc.) ) Hypoglycemic effect has been widely clinically validated. GLP-1RA weekly preparations, such as sustained release of exenatide, aliskiren and dextreotide have been listed in Europe and America, Semaglutide has entered the phase Ⅲ clinical trials. The existing clinical data show that GLP-1RA weekly preparation can safely and effectively control blood sugar, and the risk of hypoglycemia is low, the weight is decreased, the number of injections is reduced, and the medication compliance of patients is improved. This article reviews the efficacy and safety of several GLP-1RA preparations.